Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress…
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer…
Plus Therapeutics Reports Stockholders Equityin Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
August 15, 2025 07:30 ET | Source: Plus Therapeutics Inc. HOUSTON, Aug.…
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or…
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in…
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025 16:08 ET | Source: Protara Therapeutics NEW YORK, Aug.…
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025 16:05 ET | Source: Akebia Therapeutics, Inc. CAMBRIDGE, Mass.,…
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:…
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
July 29, 2025 09:01 ET | Source: Windtree Therapeutics Investors choose to…
